同步财经INCY
Incyte Shares Down 2% Premarket; Co Files for Common Stock Offering of up to 30.5 Mln Shares by Selling Stockholders
时间：2025-02-11 17:51:24 市场： 美股 综合
Incyte Files for Common Stock Offering of up to 30.5 Mln Shares by Selling Stockholders- SEC Filing
时间：2025-02-11 06:27:55 市场： 美股 综合
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (Axatilimab-Csfr) 9 Mg and 22 Mg Vial Sizes
时间：2025-01-16 06:34:35 市场： 美股 综合
Incyte Corp - Niktimvo Expected to Be Available in U.S. in Early February
时间：2025-01-16 06:34:35 市场： 美股 综合
Incyte Announces Positive Results From Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination With Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer
时间：2024-12-07 20:30:03 市场： 美股 综合
Merck Is the Latest Industry Giant to Be Linked to a Takeover Bid for Incyte- Sky News Reporter Mark Kleinman on X
时间：2024-11-20 02:36:50 市场： 美股 综合
Incyte Shares Extend After the Bell Losses, Last Down 12% at $67.65 Following Drug Study Update
时间：2024-11-19 06:26:49 市场： 美股 综合
Incyte Corp Shares Down 5% at $72.99 After the Bell Following Announcement to Pause Enrollment in Phase 2 Study Related to Chronic Spontaneous Urticaria
时间：2024-11-19 05:34:48 市场： 美股 综合
Incyte - It Will Pause Enrollment in Ongoing Phase 2 Study of Mrgprx2 (Incb000262) in Chronic Spontaneous Urticaria
时间：2024-11-19 05:30:01 市场： 美股 综合
Incyte Provides Update on Early Phase Mrgprx2 and Mrgprx4 Programs
时间：2024-11-19 05:30:01 市场： 美股 综合